Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Phosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1

Class:IdReaction:9664976
_displayNamePhosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1
_doReleaseTRUE
_timestamp2019-11-12 18:16:23
authored[InstanceEdit:9656339] Orlic-Milacic, Marija, 2019-07-31
catalystActivity[CatalystActivity:9664973] protein tyrosine kinase activity of Phosphorylated heterodimers of ERBB2 KD mutants:SHC1 [plasma membrane]
compartment[Compartment:70101] cytosol
[Compartment:876] plasma membrane
created[InstanceEdit:9664972] Orlic-Milacic, Marija, 2019-10-28
disease[Disease:1500689] cancer
edited[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
entityFunctionalStatus[EntityFunctionalStatus:9664971] gain_of_function of Phosphorylated heterodimers of ERBB2 KD mutants:SHC1 [plasma membrane]
input[Complex:9664947] Phosphorylated heterodimers of ERBB2 KD mutants:SHC1 [plasma membrane] [Homo sapiens]
[SimpleEntity:113592] ATP [cytosol]
[SimpleEntity:113592] ATP [cytosol]
isChimericFALSE
literatureReference[LiteratureReference:9649397] Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib
[LiteratureReference:9646776] EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
[LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer
[LiteratureReference:9646787] Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
[LiteratureReference:9646758] Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
[LiteratureReference:9650849] Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations
[LiteratureReference:9647026] An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
[LiteratureReference:9652195] Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2
[LiteratureReference:9664473] Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism
[LiteratureReference:9646962] Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity
[LiteratureReference:9646964] Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
[LiteratureReference:9665642] HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
modified[InstanceEdit:9665666] Orlic-Milacic, Marija, 2019-10-31
[InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
namePhosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1
normalReaction
output[Complex:9664975] Phosphorylated heterodimers of ERBB2 KD mutants:p-Y349,Y350-SHC1 [plasma membrane] [Homo sapiens]
[SimpleEntity:29370] ADP [cytosol]
[SimpleEntity:29370] ADP [cytosol]
precedingEvent
releaseDate2019-12-10
reviewed[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9664978] R-HSA-9664976.2
summation[Summation:9664974] For the following ERBB2 KD mutants that were shown to activa...
(hasEvent)[Pathway:9664565] Signaling by ERBB2 KD Mutants [Homo sapiens]
(precedingEvent)[Reaction:9664983] Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1 [Homo sapiens]
(updatedInstance)[_UpdateTracker:9835725] Update Tracker - [Reaction:9664976] Phosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1 - v85:[modifyText]
[Change default viewing format]
No pathways have been reviewed or authored by Phosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1 (9664976)